reports
- Hybridan Team
- Jon Levinson
Hybridan Small Cap Feast: 29/01/2025
Banquet Buffet**** Angle 15.25p £42.75m (AGL.L) The innovative liquid biopsy Company with circulating tumour cell (CTC) solutions for research, drug development and clinical oncology reports successful trial results. Its dual circulating tumour DNA (ctDNA) and CTC-DNA workflow used, for the first time, an end-to-end Illumina solution for analysis. In the study, CTCs were isolated and harvested using the Parsortix system from a single blood tube taken from 27 lung cancer patients. CTCs and ...
- Andy Hanson
- Bob Liao
- Brendan Long
- Carl Smith
- Daniel Slater
- David Seers
- John Cummins
- Rachel Birkett
- Robin Byde
- Robin Savage
Audio Note: Zeus Top Picks for 2025
Welcome to Zeus’ Top Picks 2025. Every year since 2021 Zeus analysts have selected their highest conviction UK SMID cap stocks over a one-year investment horizon. In 2024 Zeus analysts selected nine stocks across various sectors, focusing predominantly on the UK AIM market. These stocks provided an average total return of 16.3%, beating the AIM All Share benchmark by 18.7ppts*.
- Andy Hanson
- Bob Liao
- Brendan Long
- Carl Smith
- Daniel Slater
- David Seers
- John Cummins
- Rachel Birkett
- Robin Byde
- Robin Savage
Zeus Top Picks for 2025
Welcome to Zeus’ Top Picks 2025. Every year since 2021 Zeus analysts have selected their highest conviction UK SMID cap stocks over a one-year investment horizon. In 2024 Zeus analysts selected nine stocks across various sectors, focusing predominantly on the UK AIM market. These stocks provided an average total return of 16.3%, beating the AIM All Share benchmark by 18.7ppts*.
- Emily Liu
Hybridan Small Cap Feast 13 June 2024
13th June 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objecti...
Tracsis : 1 director
A director at Tracsis maiden bought 4,814 shares at 872p and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Hybridan Small Cap Feast - 22 Feb 24
22st February 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obj...
- Liberum Research Team
Hybridan Small Cap Feast - 03 Apr 23
3 April 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objective...
- Liberum Research Team
- Liberum Research Team
- Ciaran Donnelly
- William Larwood
LIBERUM: Tracsis - A period of strong progress
Tracsis has delivered another period of strong performance. H1’23 revenue grew 34% (13% organically) and adj. EBITDA grew 21%. During the period management has made good progress in delivering its long-term strategic goals. Part of this was building the foundations for future growth. There was £0.8m of one-off costs in H1 (including £0.4m payment of a cost-of-living bonus). As a result, adj. EBITDA margin was down yoy, but exc. the impact from the one offs, the margin was in line with H1’22 at 2...
Hybridan Small Cap Feast - 23 Feb 23
23 February 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objec...
- Liberum Research Team
SRP SERCO GROUP PLC
HAS HAYS PLC
MGNS MORGAN SINDALL GROUP
GNS GENUS PLC
HWDN HOWDEN JOINERY GROUP PLC
TRCS TRACSIS
SRC SIGMAROC
AAL ANGLO AMERICAN
A2DVHX SUPERMARKET INCOME REIT PLC
HONY HONEYCOMB INVESTMENT TRUST
TRR TRIDENT ROYALTIES
HE1 HELIUM ONE GLOBAL
WISE WISE PLC
BYIT BYTES TECHNOLOGY GROUP PLC
AA4 AMEDEO AIR FOUR PLUS LTD
- Liberum Research Team
- Ciaran Donnelly
- William Larwood
LIBERUM: Tracsis - Attractive investment case firmly intact
Tracsis is exposed to structural growth driven by the digitisation of the rail industry. This is highlighted by the 34% (inc. M&A) growth delivered in H1 23. We prudently forecast that the business will deliver 8% revenue CAGR and adj. EBITDA margin will increase to 22.3% by FY25E (from 20.6%). Management is currently investing in integrating the Group activities, technology, and operating model. This will deliver margin benefits predominantly from FY24 onwards and position the business for long...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.